Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Oct 16 - Oct 21
P., Siskind, D
A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)
Deng, S
Kratz F, Drevs J, Bing G, Stockmar C, Scheuermann K, Lazar P, Unger C: Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates
Clinical trials have shown that weight loss may continue for up to 68 weeks or longer with consistent treatment
US$ 24.24
US$ 22.60
US$ 20.19
US$ 21.69
US$ 23.67
US$ 28.38
